Developments in cancer vaccines for hepatocellular carcinoma

Luigi Buonaguro, HEPAVAC Consortium, Yuk Ma (Contributor), David Adams (Contributor)

Research output: Contribution to journalArticlepeer-review

32 Citations (Scopus)


Hepatocellular carcinoma (HCC) accounts for about 6 % of all new cancers diagnosed worldwide and represents one of the leading causes of cancer-related death globally in men and women, respectively. The overall prognosis for HCC patients is poor, especially in the majority of patients with more advanced stage of disease. Indeed, in such cases immunotherapeutic strategies may represent a novel and effective tool. A few immunotherapy trials conducted for HCC have provided divergent results, urging the scientific community to explore additional paths to improve efficacy of immunotherapeutic approaches. The "Cancer Vaccine development for Hepatocellular Carcinoma"-HEPAVAC Consortium has been funded by the EU within the FP7 with the goal of developing a novel therapeutic peptide-based cancer vaccine strategy for HCC including both "off-the-shelf" and personalized antigens. This will be one of the very few vaccine trials for HCC and the first multi-epitope, multi-target and multi-HLA allele therapeutic cancer vaccine for such a frequent and aggressive disease with a hitherto high unmet medical need. Feasibility, safety and biological efficacy will be evaluated in a randomized, controlled European multicenter phase I/II clinical trial.

Original languageEnglish
Article number93
JournalCancer Immunology Immunotherapy
Publication statusPublished - 21 Jun 2015


Dive into the research topics of 'Developments in cancer vaccines for hepatocellular carcinoma'. Together they form a unique fingerprint.

Cite this